Belluscura focuses on novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Its range of portable products will be lighter, more adaptable and have higher O₂ capacity than existing oxygen enrichment products. Whilst potentially useful for recovering COVID patients, it has a wide range of use for sufferers of pneumonia, COPD (i.e. asthma, emphysema and chronic bronchitis) and other respiratory illnesses.
It received 510(k) clearance from the US Food & Drug Administration (FDA) in March 2021 for its X-PLO₂R range of oxygen concentrators, which will be launched in 2021.
The Company has a registered office in the UK. Its subsidiary, Belluscura LLC, is based in Plano, Texas, USA. The USA is the Company’s main country of operation.
Inaugural Annual Report
Having helped Bellusura and their advisers with the production of their IPO admission document when they floated on AIM in May 2021, the Perivan shareholder communications team were delighted to provide their annual report production expertise which was published to their new shareholders on 1st April, at this important stage of the Company’s corporate journey.
To view the full annual report, click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.